MNG861
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.383
- TGF_BETA_SIGNALING+0.283
- DNA_REPAIR+0.234
- E2F_TARGETS+0.229
- MITOTIC_SPINDLE+0.219
- G2M_CHECKPOINT+0.199
- INTERFERON_ALPHA_RESPONSE+0.150
- MYC_TARGETS_V1+0.130
- UV_RESPONSE_DN+0.128
- PI3K_AKT_MTOR_SIGNALING+0.115
Top 10 suppressed
- ANGIOGENESIS-0.483
- APICAL_SURFACE-0.411
- INFLAMMATORY_RESPONSE-0.401
- ALLOGRAFT_REJECTION-0.391
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.388
- PANCREAS_BETA_CELLS-0.358
- HEDGEHOG_SIGNALING-0.332
- KRAS_SIGNALING_UP-0.331
- KRAS_SIGNALING_DN-0.327
- ESTROGEN_RESPONSE_LATE-0.326
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG903 | — | — | 0.855 |
| 2 | R337 | — | — | 0.832 |
| 3 | R4 | — | — | 0.828 |
| 4 | R90 | — | — | 0.824 |
| 5 | SRR5088921 | — | — | 0.823 |
| 6 | TCGA-GC-A3BM-01A-11R-A22U-07 | — | — | 0.820 |
| 7 | SRR8613766 | — | D | 0.815 |
| 8 | 09c2c2d4-0d2f-488e-b42e-9c4756a27940 | — | — | 0.813 |
| 9 | SRR5088920 | — | — | 0.812 |
| 10 | R27 | — | — | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.383 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.283 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.234 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.229 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.219 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.199 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.150 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.128 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.115 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.075 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.064 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.027 | Inavolisib | — uncovered |